Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 4
2005 4
2006 9
2007 2
2008 6
2009 3
2010 7
2011 7
2012 5
2013 3
2014 2
2015 3
2016 6
2017 5
2018 11
2019 8
2020 15
2021 26
2022 15
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for su wei wen
Search for Shu-Wei Wen instead (2 results)
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Non-viral 2A-like sequences for protein coexpression.
Su WW, Zhang B, Han Z, Kumar S, Gupta M. Su WW, et al. J Biotechnol. 2022 Nov 10;358:1-8. doi: 10.1016/j.jbiotec.2022.08.014. Epub 2022 Aug 20. J Biotechnol. 2022. PMID: 35995093
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
Chang TS, Huang CF, Kuo HT, Lo CC, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Hung CH, Yu ML. Chang TS, et al. Among authors: su ww. Hepatol Int. 2023 Jun;17(3):550-561. doi: 10.1007/s12072-023-10506-z. Epub 2023 Mar 27. Hepatol Int. 2023. PMID: 36973633 Free PMC article.
Retinoblastoma in Taiwan: survival and clinical characteristics.
Chen PY, Kao LY, Chao AN, Wu WC, Sun MH, Su WW, Liu CH. Chen PY, et al. Among authors: su ww. Jpn J Ophthalmol. 2021 Jul;65(4):546-553. doi: 10.1007/s10384-021-00836-6. Epub 2021 May 4. Jpn J Ophthalmol. 2021. PMID: 33948759
Visual Subfield Progression in Glaucoma Subtypes.
Su WW, Hsieh SS, Cheng ST, Su CW, Wu WC, Chen HS. Su WW, et al. J Ophthalmol. 2018 Mar 21;2018:7864219. doi: 10.1155/2018/7864219. eCollection 2018. J Ophthalmol. 2018. PMID: 29750123 Free PMC article.
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Chen CY, Yu ML; T-COACH Study Group. Tsai PC, et al. Among authors: su ww. J Hepatol. 2023 Feb;78(2):281-292. doi: 10.1016/j.jhep.2022.09.019. Epub 2022 Oct 5. J Hepatol. 2023. PMID: 36208843
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Lu MY, Huang CF, Hung CH, Tai CM, Mo LR, Kuo HT, Tseng KC, Lo CC, Bair MJ, Wang SJ, Huang JF, Yeh ML, Chen CT, Tsai MC, Huang CW, Lee PL, Yang TH, Huang YH, Chong LW, Chen CL, Yang CC, Yang SS, Cheng PN, Hsieh TY, Hu JT, Wu WC, Cheng CY, Chen GY, Zhou GX, Tsai WL, Kao CN, Lin CL, Wang CC, Lin TY, Lin CL, Su WW, Lee TH, Chang TS, Liu CJ, Dai CY, Kao JH, Lin HC, Chuang WL, Peng CY, Tsai CW, Chen CY, Yu ML; TACR Study Group. Lu MY, et al. Among authors: su ww. Clin Mol Hepatol. 2024 Jan;30(1):64-79. doi: 10.3350/cmh.2023.0287. Epub 2023 Nov 21. Clin Mol Hepatol. 2024. PMID: 38195113 Free PMC article.
145 results